Compare Citius Pharmaceuticals Inc (CTXR) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ecopetrol SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Ecopetrol SA trades at $17.17 (market cap $33.11B). The key difference: Ecopetrol SA is far larger — about 2431× Citius Pharmaceuticals Inc's market cap, and Ecopetrol SA pays a 3.83% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Ecopetrol SA for 84 Days on average.
| CTXR | EC | |
|---|---|---|
Market Cap | $13.62M | $33.11B |
Volume | 132,438 | 993,598 |
Sector | Health | Energy |
52-Week High | $1.82 | $18.26 |
52-Week Low | $0.48 | $8.61 |
Typical Hold Time | 16 Days | 84 Days |
Enterprise Value | $3.79M | $61.36B |
Dividend Yield | — | 3.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Ecopetrol (EC) trades at $16.63, down 1.95% amid bearish technical signals and recent earnings misses. The stock shows attractive valuation metrics with P/E of 7.97 and P/S of 0.91, but faces declining revenue trends from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while analyst sentiment remains cautious with 27% buy ratings.
The outlook remains challenged by declining profitability and political interference risks, though current valuations appear discounted. Investment opportunity exists if new management can stabilize operations, but investors face headwinds from earnings volatility and geopolitical factors in Colombia's state-controlled energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
